Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma ...

Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. As global markets navigate a mixed economic landscape marked by declining ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and ...

GRIFOLS transfer bags are used for sterile preservation and administration of blood components. Blood components can be obtained, stored and preserved without contact with the environment ensuring ...